Credit: Shutterstock. Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major cardiovascular adverse events (MACE) for those taking ustekinumab (Stelara) versus ...

The new diabetes test helps identify patients with type 1 diabetes The FDA has approved vedolizumab for patients with inadequate response to conventional therapies. The U.S. Food and Drug ...

LAS VEGAS — In a comparison of data from clinical trials for ulcerative colitis, ozanimod (Zeposia) appeared to be more useful than adalimumab (Humira) and as useful as vedolizumab (Entyvio). The US ...

CHICAGO -- Patients receiving vedolizumab (Entyvio) after undergoing bowel resection for advanced Crohn's disease in a randomized trial were significantly less likely to show endoscopic signs of ...